Physician profile
Brian A Grus
NPI 1053421065
$509.50
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $15.16 · 2022: $114 · 2023: $178 · 2024: $52.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $114.09 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $110.27 | 2019-2024 | |
| Lilly USA, LLC | $101.55 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $51.59 | 2022 | |
| Abbott Laboratories | $45.81 | 2019 | |
| Amgen INC. | $30.83 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.80 | 2019 | |
| Novo Nordisk INC | $16.65 | 2024 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Grus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.